Left ventricular diastolic dysfunction induced by cyclophosphamide in blood stem cell transplantation

Japanese Heart Journal

Volumn 43, Issue 3, 2002, Pages 249-261

  Mori, Tadashi ^a   Yanagi, Nobuhito ^a   Maruyama, Toru ^b   Gondo, Hisashi ^a   Okamura, Takashi ^c   Kaji, Yoshikazu ^a   Harada, Mine ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KURUME UNIVERSITY   (Japan)

Author keywords

Cardiotoxicity; Cyclophosphamide; Signal averaged electrocardiogram; Stem cell transplantation; Ultrasound cardiogram

Indexed keywords

BUSULFAN; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; MELPHALAN; RANIMUSTINE; ALKYLATING AGENT;

ADOLESCENT; ADULT; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLE; DRUG DOSE REGIMEN; ECHOCARDIOGRAPHY; FEMALE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE SIZE; HEART MUSCLE POTENTIAL; HEART VENTRICLE SEPTUM; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MYCOSIS; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; QRS COMPLEX; SCHOOL CHILD; SIGNAL AVERAGED ELECTROCARDIOGRAPHY; STATISTICAL ANALYSIS; SYSTOLE; BLOOD DISEASE; CHEMICALLY INDUCED DISORDER; CHILD; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD; CYCLOPHOSPHAMIDE; DIASTOLE; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; TRANSPLANTATION CONDITIONING; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0036559477     PISSN: 00214868     EISSN: 1348673X     Source Type: Journal    
DOI: 10.1536/jhj.43.249     Document Type: Article

References (33)

1. Kantrowitz NE, Bristow MR. Cardiotoxicity of antitumor agents. Prog Cardiovasc Dis 1984; 27: 195-200.
2. Lancaster LD, Ewy GA. Cardiac consequences of malignancy and their treatment. Adv Intern Med 1984; 30: 275-93.
3. Cazin B, Gorin NC, Laporte JP, et al. Cardiac complications after bone marrow transplantation: a report on a series of 63 consecutive transplantations. Cancer 1986; 57: 2061-9.
4. Sawabe T, Mizuno S, Gondo H, Maruyama T, Niho Y. Sinus arrest during tacrolimus (FK 506) and digitalis treatment in a bone marrow transplant recipient. Transplantation 1997; 64: 182-3.
5. Sawabe T, Maruyama T, Mizuno S, Gondo H, Niho Y. Reply to "Sinus arrest during tacrolimus treatment: was the QT interval prolonged?" Transplantation 1999; 66: 403-4.
6. Freter CE, Lee TC, Billingham ME, Chak L, Bristow MR. Doxorubicin cardiac toxicity manifesting seven years after treatment. Am J Med 1986; 80: 483-5.
7. Steinherz LJ, Steinherz P. Cardiac failure more than six years post anthracyclines (abstr). Am J Cardiol 1988; 62: 505.
8. Wortman JE, Lucas VS Jr, Schuster E, Thiele D, Logue GL. Sudden death during doxorubicin administration. Cancer 1979; 44: 1588-91.
9. Hochster H, Wasserheit C, Speyer J. Cardiotoxicity and cardioprotection during chemotherapy. Curr Opinion Oncol 1995; 7: 304-9.
10. Henry WL, DeMaria A, Gramiak R, et al. Report of the American Society of Echocardiography committee on nomenclature and standards in two-dimensional echocardiography. Circulation 1980; 62: 212-5.
11. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence or absence of asynergy. Am J Cardiol 1976; 37: 7-11.
12. Simson MB. Use of signals in the terminal QRS complex to identify patients with ventricular tachycardia after myocardial infarction. Circulation 1981; 64: 235-42.
13. Denes P, Santarelli P, Hauser R, Uretz EF. Quantitative analysis of the high-frequency components of the terminal portion of the body surface QRS in normal subjects and in patients with ventricular tachycardia. Circulation 1983; 67: 1129-38.
14. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-8.
15. Santos GW, Sensenbrenner LL, Burke PJ, et al. Marrow transplantation in man following cyclophosphamide. Transplant Proc 1971; 3: 400.
16. Buckner CD, Rudolph RH, Fefer A, et al. High-dose cyclophosphamide therapy for malignant disease. Cancer 1972; 29: 357-65.
17. Mullins GM, Anderson PN, Santos GW. High dose cyclophosphamide therapy in solid tumors. Cancer 1975; 36: 1950-8.
18. Buja LM, Ferrans VJ, Graw RG Jr. Cardiac pathologic findings in patients treated with bone marrow transplantation. Human Pathol 1976; 7: 17-45.
19. Mills BA, Roberts RW. Cyclophosphamide-induced cardiomyopathy. Cancer 1979; 43: 2223-6.
20. von Bernuth G, Adam D, Hofstetter R, et al. Cyclophosphamide cardiotoxicity. Eur J Pediatr 1980; 134: 87-90.
21. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981; 141: 758-63.
22. Gardner SF, Lazarus HM, Bednarczyk EM, et al. High-dose cyclophosphamide-induced myocardial damage during BMT: assessment by positron emission tomography. Bone Marrow Transplant 1993; 12: 139-44.
23. Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986; 68: 1114-8.
24. Allen SJ. The pathophysiology of myocardial edema: principles of myocardial fluid balance. Curr Opinion Anaesthesiol 1994; 7: 12-7.
25. Garcia-Dorado D, Oliveras J. Myocardial oedema: a preventable cause of reperfusion injury? Cardiovasc Res 1993; 27: 1555-63.
26. Whittingham TA. New and future developments in ultrasonic imaging. Br J Radiol 1997; 70: S119-32.
27. Spencer KT, Bednarz J, Rafter PG, et al. Use of harmonic imaging without echocardiographic contrast to improve two-dimensional image quality. Am J Cardiol 1998; 82: 794-9.
28. Honma H, Kusama Y, Matsuzaki T, et al. Resting ultrasonic tissue characterization and dobutamine stress echocardiography for prediction of functional recovery in chronic left ventricular ischemic dysfunction. Jpn Circ J 2001; 65: 381-8.
29. Facchini M, Malfatto G, Ciambellotti F, et al. Increased left ventricular dimensions in patients with frequent nonsustained ventricular arrhythmia and no evidence of underlying heart disease. J Cardiovasc Electrophysiol 1999; 10: 1433-8.
30. Hauser AM, Gordon S, Cieszkowski J, Timmis GC. Severe transient left ventricular 'hypertrophy' occurring during acute myocarditis. Chest 1983; 83: 275-7.
31. Liao PK, Seward JB, Hagler DJ, Driscoll DJ. Acute myocarditis associated with transient marked myocardial thickening and complete atrioventricular block. Clin Cardiol 1984; 7: 356-62.
32. Nakagawa M, Hamaoka K. Myocardial thickening in children with acute myocarditis. Chest 1993; 104: 1676-8.
33. Hiramitsu S, Morimoto S, Kato S, et al. Transient ventricular wall thickening in acute myocarditis: a serial echocardiographic and histologic study. Jpn Circ J 2001; 65: 863-6.